Adding to its pain portfolio, Eli Lilly has entered into a global licensing agreement with Confo Therapeutics for the latter’s lead asset, CFTX-1554, a Phase I oral inhibitor of the angiotensin II type 2 receptor for the treatment of neuropathic pain. In return, Confo will receive US$40 M upfront as well as an additional US$590 M in milestones if Lilly decides to advance another antibody-based inhibitor targeting the same receptor. Despite the field facing multiple setbacks in previous years, Lilly continues to invest in non-opioid pain drugs.